Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

NCT04688788 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

600

Enrollment

OTHER

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis

Interventions

DRUG: Rituximab
DRUG: Ocrelizumab
DRUG: Fexofenadine
DRUG: Paracetamol
DRUG: Methylprednisolone

Sponsor

Rigshospitalet, Denmark

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]